title: A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.
abstract: OBJECTIVE
  To identify the contribution of individual isoform (α, β, γ, δ) of class I PI3Ks to tumor cell growth for proper use of PI3K inhibitors in cancer therapy.
  
  
  METHODS
  A panel of human rhabdomyosarcoma Rh30 cells stably expressing myristoylation (Myr)-tagged one of class I PI3K p110 subunits was established. PI3K activity was analyzed by measuring phosphorylated Akt with Western blotting, and isoform-specific PI3K activities were validated with PI3K isoform-selective inhibitors. The growth of prostate cancer PC-3 cells and B cell type leukemia Raji cells was determined using SRB assay and CCK-8 assay, respectively.
  
  
  RESULTS
  The phosphorylation of Akt in Rh30-Myr-p110α, β, γ, δ cells was preferentially inhibited by PI3K isoform-selective inhibitors A66 (PI3Kα), TGX221 (PI3Kβ), AS604850 (PI3Kγ) and CAL-101 (PI3Kδ), respectively. A newly obtained PI3K inhibitor WJD008 (10 μmol/L) completely abrogated Akt phosphorylation by all the isoforms of class I PI3Ks, thus acted as a pan-PI3K inhibitor. In prostate cancer PC-3 cells, the PI3K isoform-selective inhibitors were much less potent than WJD008 in suppression of the proliferation. In B cell type leukemia Raji cells, inhibition of PI3Kδ alone or all the isoforms of class I PI3Ks displayed similar potency against the cell proliferation, whereas selective inhibition of individual PI3Kα/β/γ isoforms resulted in negligible activity.
  
  
  CONCLUSIONS
  Rh30-Myr-p110α, β, γ, δ cells are a useful cell model to identify the selectivity of PI3K inhibitors. Pan-PI3K inhibitors are suitable for treating PC-3 cells, whereas selective PI3Kδ inhibitor is sufficient to block Raji cell growth. The biased dependency on PI3K isoforms for tumor cell growth rationalizes the use of PI3K inhibitors with different selectivity for cancer therapy.
authors.affiliation: Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
authors.forename: Xiang
authors.initials: X
authors.lastname: Wang
authors.forename: Jia-peng
authors.initials: JP
authors.lastname: Li
authors.forename: Yan
authors.initials: Y
authors.lastname: Yang
authors.forename: Jian
authors.initials: J
authors.lastname: Ding
authors.forename: Ling-hua
authors.initials: LH
authors.lastname: Meng
mesh_terms: D001483:Base Sequence; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000378:metabolism; D008969:Molecular Sequence Data; D009025:Morpholines / Q000494:pharmacology*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011743:Pyrimidines / Q000494:pharmacology*
chemical_list: D007527:Isoenzymes; D009025:Morpholines; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011743:Pyrimidines; C552255:4-(2-(dimethylamino)vinyl)-2-(3-hydroxyphenyl)-6-morpholinopyrimidine-5-carbonitrile
references.citation: Eur J Pharmacol. 2008 Jun 10;587(1-3):209-15
references.pmid: 18455722
references.citation: Biochem J. 2011 Aug 15;438(1):53-62
references.pmid: 21668414
references.citation: Cancer Res. 2010 Feb 1;70(3):1164-72
references.pmid: 20103642
references.citation: Nat Med. 2005 Sep;11(9):936-43
references.pmid: 16127437
references.citation: Cell. 2006 May 19;125(4):733-47
references.pmid: 16647110
references.citation: Blood. 2010 Sep 2;116(9):1460-8
references.pmid: 20505158
references.citation: Biosystems. 2012 Sep;109(3):403-11
references.pmid: 22525052
references.citation: Cold Spring Harb Perspect Biol. 2012 Sep 01;4(9):a011189
references.pmid: 22952397
references.citation: Acta Pharmacol Sin. 2012 Dec;33(12):1441-58
references.pmid: 22983389
references.citation: Future Med Chem. 2012 Jun;4(9):1153-69
references.pmid: 22709255
references.citation: Cancer Cell. 2012 Apr 17;21(4):459-72
references.pmid: 22516257
references.citation: Acta Pharmacol Sin. 2010 Sep;31(9):1189-97
references.pmid: 20729870
references.citation: Cancer Res. 2010 Mar 15;70(6):2146-57
references.pmid: 20179189
references.citation: Biochem J. 2012 Mar 15;442(3):465-81
references.pmid: 22364281
references.citation: Adv Enzyme Regul. 2011;51(1):106-16
references.pmid: 21035500
references.citation: Chem Biol. 2010 Feb 26;17(2):123-34
references.pmid: 20189103
references.citation: Adv Biol Regul. 2012 Sep;52(3):389-405
references.pmid: 22884032
references.citation: Acta Pharmacol Sin. 2012 Apr;33(4):531-41
references.pmid: 22426696
references.citation: Biochem J. 2007 Jun 15;404(3):449-58
references.pmid: 17362206
references.citation: Nature. 2008 Aug 7;454(7205):776-9
references.pmid: 18594509
references.citation: Cancer Discov. 2012 May;2(5):425-33
references.pmid: 22588880
references.citation: Cancer Cell. 2006 May;9(5):341-9
references.pmid: 16697955
references.citation: Blood. 2010 Sep 23;116(12):2078-88
references.pmid: 20522708
references.citation: Curr Hematol Malig Rep. 2010 Jan;5(1):29-34
references.pmid: 20425394
references.citation: J Pharmacol Exp Ther. 2010 Sep 1;334(3):830-8
references.pmid: 20522531